IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below: Grant Support/Research Contract - Conformal; Edwards Lifesciences Consultant ...
Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and ...
ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...
Edwards delivered third-quarter results with revenue growth at 13% in constant currency, which included the 53% rise in transcatheter tricuspid and mitral valve sales. New data shared at a recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results